Roche to unveil lung, breast cancer data at ESMO 2026
RHHBY wins FDA approval for Enspryng in thyroid eye disease, offering the first and only at-home subcutaneous treatment option for patients.
RHHBY expands its obesity pipeline with a novel RNAi candidate targeting ALK7, while advancing enicepatide and other late-stage drugs to strengthen its metabolic disease ambitions.
| Pharmaceuticals Industry | Healthcare Sector | Thomas Schinecker CEO | XFRA Exchange | 771195104 CUSIP |
| CH Country | 103,249 Employees | 13 Mar 2026 Last Dividend | 27 Feb 2014 Last Split | - IPO Date |
Roche Holding AG is a globally recognized healthcare company that combines its strengths in both pharmaceuticals and diagnostics. With a rich heritage dating back to 1896, the company has established a significant presence across various continents including Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. Roche is committed to improving health and well-being by providing innovative solutions and cutting-edge products in multiple therapeutic areas and diagnostics. The company's headquarters are strategically located in Basel, Switzerland, ensuring a pivotal role in the global healthcare sector.
Roche Holding AG offers a diverse portfolio of products and services across a broad spectrum of medical needs and diagnostic requirements. The company’s offerings can be categorized into pharmaceutical products and diagnostic solutions.
Through its relentless pursuit of innovation and its expansive portfolio, Roche Holding AG is at the forefront of shaping the future of healthcare by addressing some of the most challenging medical needs and advancing global health.